Estradiol didrogesterone tablet composition as well as preparation method and application thereof
Through the double-layer tablet structure and step-by-step granulation technology, the problems of low estradiol dissolution rate and excessively fast dedradiol dissolution rate in estradiol dedradiol tablets were solved, and high bioavailability and Stability, reduces stomach irritation, and is suitable for industrial production.
Patent Information
- Application Number
- CN202411145207.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-29
AI Technical Summary
The existing estradiol dedrectone tablets have low estradiol dissolution rate, low bioavailability, and excessive dedrectone dissolution rate, resulting in stomach irritation and discomfort symptoms such as stomach pain, nausea, and vomiting.
Using a double-layer tablet structure, sodium dodecyl sulfate and estradiol composition are granulated together by step-by-step granulation and double-layer tableting technology, and the dedroxygenone composition is granulated together, using the The solvent increases the dissolution rate of estradiol and adjusts the dissolution rate of dedragoneone through a binder and a disintegrant, avoiding direct contact between the two and improving the stability of the active ingredient.
It improves the dissolution rate and accumulated dissolution rate of estradiol, ensures high bioavailability of the drug, and at the same time makes the dissolution rate of dedrouterone moderate, reduces the irritation to the stomach, and has high stability of the active ingredients. Suitable for industrial production.
Smart Images

Figure BDA0005002018810000051 
Figure BDA0005002018810000052 
Figure BDA0005002018810000071
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicines, and in particular relates to an estradiol dydrogesterone tablet composition, a preparation method and an application thereof. Background Art
[0002] Estradiol Dydrogesterone Tablets are estrogen-progesterone compound preparations composed of estradiol and dydrogesterone, with the active ingredients being estradiol hemihydrate and dydrogesterone. Estradiol Dydrogesterone Tablets are steroid drugs developed by Abbott and are used in combination with estradiol to treat perimenopausal syndrome caused by natural or postoperative menopause. Estradiol Tablets / Estradiol Dydrogesterone Tablets combined packaging was launched in China in 2010 under the trade name: Femoston. Currently, there is relatively little research on compound generic estradiol dydrogesterone tablets.
[0003] CN116036033A discloses a dydrogesterone tablet and its production process. The dydrogesterone tablet includes a tablet and a coating. The tablet includes a first drug-administering layer, a barrier layer and a second drug-administering layer arranged in sequence. The raw material components of the first drug-administering layer and the second drug-administering layer include dydrogesterone, starch, sodium carboxymethyl cellulose, sodium carboxymethyl starch, hydrogenated vegetable oil and sodium lauryl sulfate. The raw material components of the barrier layer include modified sodium alginate, hydroxypropyl methylcellulose, magnesium stearate, isomalt, sea mussel shell extract and water. The barrier layer in the application slows down the dissolution rate of the first drug-administering layer, thereby reducing the stimulation of the tablet to the stomach, avoiding stomach pain, nausea, vomiting and the like. However, the solubility of the drug is low, only reaching about 60%.
[0004] CN117180214A discloses a dydrogesterone tablet composition and a preparation method thereof. By optimizing the composition and content of the filler, lactose is combined with at least one of corn starch, microcrystalline cellulose, mannitol, and sodium carboxymethyl starch, and the lactose content is in the range of 64%-86% of the tablet composition, so that the tablet composition has the best dissolution effect, fast dissolution rate, high cumulative dissolution rate, and complete dissolution; and has excellent stability. However, the drug dissolves too fast, which greatly irritates the stomach, causing stomach pain, nausea, vomiting, etc.
[0005] CN101094656A discloses an oral solid dosage form, which contains estradiol or its hydrate, salt or pharmaceutically acceptable derivative; and at least one pharmaceutically acceptable excipient, wherein the amount of estradiol or its hydrate, salt or pharmaceutically acceptable derivative is therapeutically equivalent to estradiol hemihydrate in an amount of 0.01 mg to 0.5 mg, provided that when polyvinyl pyrrolidone is present, the weight ratio of polyvinyl pyrrolidone to estradiol is less than 10:1, and the dosage form is formulated in a manner that avoids estradiol degradation and minimizes the content of polyvinyl pyrrolidone, while also achieving similar rapid dissolution of estradiol. However, the drug still has the risk of estradiol degradation during long-term placement, and the improvement of estradiol dissolution rate is limited.
[0006] In the prior art, the estradiol dydrogesterone tablet compound has the problems of low estradiol dissolution rate, low bioavailability, and too fast dydrogesterone dissolution rate, which greatly stimulates the stomach and causes stomach pain, nausea, vomiting, etc. Therefore, it is very necessary to provide a technical estradiol dydrogesterone tablet composition and production process to solve the above problems. Summary of the invention
[0007] The technical problem to be solved by the present invention is to overcome the deficiencies and defects mentioned in the above background technology and provide an estradiol dydrogesterone tablet composition and a preparation method and application thereof.
[0008] In order to solve the above technical problems, the technical solution proposed by the present invention is:
[0009] An estradiol dydrogesterone tablet composition comprises the following components in parts by weight:
[0010] 1.0-2.5 parts of estradiol, 7.5-12.5 parts of dydrogesterone, 100-115 parts of filler, 10-18 parts of disintegrant, 1.5-3.5 parts of binder, 0.7-1.4 parts of solubilizer, 0.8-1.8 parts of glidant and 0.5-1 part of lubricant;
[0011] The solubilizing agent is sodium lauryl sulfate.
[0012] As a further improvement, it is a double-layer tablet, wherein one layer comprises dydrogesterone, a filler, a disintegrant, a binder, a glidant and a lubricant, and the other layer comprises estradiol, a filler, a disintegrant, a binder, a solubilizer, a glidant and a lubricant.
[0013] As a further improvement, the weight portions of filler, disintegrant, binder, glidant and lubricant in the two layers of the double-layer tablet are the same.
[0014] As a further improvement, the particle size of the estradiol is controlled to be less than 11 μm at D90.
[0015] As a further improvement, the composition further comprises 3 to 5 parts of a coating agent.
[0016] As a further improvement, the filler includes one or more of lactose, mannitol, sorbitol, dextrin or maltodextrin.
[0017] As a further improvement, the disintegrant includes one or more of corn starch, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose or low-substituted hydroxypropyl cellulose.
[0018] The present invention also provides a method for preparing the estradiol dydrogesterone tablet composition, comprising the following steps:
[0019] S1. Evenly mix dydrogesterone with part of the filler, part of the disintegrant and part of the glidant, add part of the binder to granulate, and mix with part of the lubricant after drying;
[0020] S2. The estradiol and the solubilizer, the remaining filler, the remaining disintegrant and the remaining glidant are mixed uniformly, the remaining binder is added for granulation, and the mixture is dried and mixed with the remaining lubricant;
[0021] S3. The granules obtained in S1 and S2 are compressed into double-layer tablets.
[0022] As further improvements, it also includes:
[0023] S4. The double-layer tablets are made into double-layer tablets by film coating.
[0024] The present invention also provides an application of the estradiol dydrogesterone tablet composition in preparing a medicine for treating perimenopausal syndrome.
[0025] The two active ingredients in estradiol dydrogesterone tablets, estradiol and dydrogesterone, are both poorly soluble drugs, among which the dissolution rate of estradiol is relatively slow. Studies have found that by micronizing estradiol to make D90 less than 10μm, the dissolution rate of estradiol can be increased, but the ideal effect is still not achieved, and when the particle size D90 of estradiol is reduced to 10μm, further reducing the particle size does not significantly improve the dissolution rate. Adjusting the proportion of excipients cannot increase the cumulative dissolution of estradiol. Adding sodium dodecyl sulfate as a solubilizer has a significant effect on increasing the dissolution rate and cumulative dissolution of estradiol, but using conventional operations to granulate sodium dodecyl sulfate with estradiol, dydrogesterone and other excipients will simultaneously accelerate the dissolution of dydrogesterone and increase gastrointestinal irritation. It was unexpectedly found that the direct contact of estradiol, sodium lauryl sulfate, and dydrogesterone composition increased the instability of estradiol, so a two-step granulation was used, sodium lauryl sulfate was granulated together with the active ingredient estradiol and its composition, and the active ingredient dydrogesterone and its composition were granulated together, thereby increasing the dissolution rate of estradiol and making the dissolution rate of dydrogesterone moderate. The granules corresponding to the two active ingredients were then tableted using a double-layer tableting technology to avoid direct contact between estradiol, sodium lauryl sulfate, and dydrogesterone, so that the active ingredients have high stability.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] The estradiol dydrogesterone tablet composition of the present invention can not only improve the drug dissolution rate of estradiol, but also has high cumulative dissolution, thereby providing guarantee for drug absorption, high bioavailability, and at the same time making the dydrogesterone dissolution rate moderate, avoiding irritation to the stomach. Moreover, the active ingredient in the composition of the present invention has high stability. In addition, the preparation method of the estradiol dydrogesterone tablet composition of the present invention is simple to operate and suitable for industrial production. DETAILED DESCRIPTION
[0028] In order to facilitate the understanding of the present invention, the present invention will be described more comprehensively and carefully in combination with preferred embodiments below, but the protection scope of the present invention is not limited to the following specific embodiments.
[0029] Unless otherwise defined, all professional terms used below have the same meanings as those generally understood by those skilled in the art. The professional terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of protection of the present invention.
[0030] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.
[0031] In some specific embodiments, the estradiol dydrogesterone tablet composition of the present invention comprises the following components in parts by weight: 1.0-2.5 parts of estradiol, 7.5-12.5 parts of dydrogesterone, 100-115 parts of filler, 10-18 parts of disintegrant, 1.5-3.5 parts of binder, 0.7-1.4 parts of solubilizer, 0.8-1.8 parts of glidant, 0.5-1 part of lubricant and 3-5 parts of coating agent.
[0032] It is a double-layer tablet, wherein one layer comprises dydrogesterone, a filler, a disintegrant, a binder, a glidant and a lubricant, and the other layer comprises estradiol, a filler, a disintegrant, a binder, a solubilizer, a glidant and a lubricant.
[0033] The solubilizing agent of the present invention is sodium lauryl sulfate, which is used to improve the solubility of estradiol, thereby increasing the dissolution rate of estradiol. In order to improve the solubility of estradiol, technicians in the field of pharmacy usually micronize estradiol, increase the surface area of estradiol, accelerate dissolution or use excipients that promote disintegration, promote particle disintegration, and accelerate the release of estradiol. The present invention adds sodium lauryl sulfate as a solubilizing agent to enhance the wettability of the hydrophobic active ingredient estradiol, and improve the dissolution rate and cumulative dissolution of estradiol. The dosage of sodium lauryl sulfate is 0.7 to 1.4 parts, which is most suitable. If it is less than 0.7 parts, it has limited effect on improving the dissolution rate of estradiol. If it is greater than 1.4 parts, it will have an adverse effect on the stability of estradiol.
[0034] In some embodiments, fillers include lactose, mannitol, sorbitol, dextrin, maltodextrin, and the like.
[0035] In some embodiments, disintegrants include corn starch (also as a filler), sodium starch glycolate, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and the like.
[0036] In some embodiments, binders include hydroxypropyl cellulose, hypromellose, potato starch, and the like.
[0037] In some embodiments, glidants include colloidal silicon dioxide, silicon dioxide, talc, and the like.
[0038] In some embodiments, lubricants include magnesium stearate, stearic acid, sodium stearyl fumarate, and the like.
[0039] In some embodiments, the coating agent is a film coating premix.
[0040] In some specific embodiments, the preparation method of the estradiol dydrogesterone tablet composition of the present invention comprises the following steps:
[0041] (1) Mix the prescribed amount of dydrogesterone, part (preferably 1 / 2 of the prescribed amount) of filler, part (preferably 1 / 2 of the prescribed amount) of disintegrant, and part (preferably 1 / 2 of the prescribed amount) of glidant (preferably for 5 to 10 minutes).
[0042] (2) After adding a portion (preferably 1 / 2 of the prescribed amount) of the binder solution (preferably prepared to a concentration of 11 to 13 wt%) under stirring and shearing, continue granulation (preferably continue granulation for 2 to 4 minutes), sieve the wet granules, dry them, and granulate them.
[0043] (3) Add some lubricant (preferably 1 / 2 of the prescribed amount) and mix (preferably mix for 3 to 7 minutes) for later use.
[0044] (4) Mix the prescribed amount of estradiol, the solubilizer sodium lauryl sulfate, the remaining filler, the remaining disintegrant, and the remaining glidant (preferably for 5 to 10 minutes).
[0045] (5) After adding the remaining binder solution under stirring and shearing, continue granulation (preferably continue granulation for 2 to 4 minutes), sieve the wet granules, dry them, and granulate them.
[0046] (6) Add the remaining lubricant and mix (preferably for 3 to 7 minutes).
[0047] (7) Using a double-layer tablet press, the granules obtained in step (3) and step (6) are compressed into double-layer tablets.
[0048] (8) A coating agent is used to coat the tablet to form a double-layer tablet, and the coating weight gain is preferably 2-4%.
[0049] For the compound preparation of estradiol and dydrogesterone tablets, technicians in the pharmaceutical field usually granulate the two active ingredients of estradiol and dydrogesterone and their combination together. In the present invention, the two active ingredients of estradiol and dydrogesterone are granulated in two steps (sodium lauryl sulfate is granulated together with the active ingredient estradiol and its combination, and the active ingredient dydrogesterone and its combination are granulated together separately), thereby avoiding the irritation of the stomach caused by the excessively fast dissolution rate of dydrogesterone.
[0050] Unexpectedly, when sodium lauryl sulfate was used, unacceptable stability problems occurred. The direct contact of the composition of estradiol, sodium lauryl sulfate and dydrogesterone increased the instability of estradiol. Therefore, the present invention uses a double-layer tableting technology to compress the particles corresponding to the two active ingredients, so that estradiol has good stability.
[0051] Therefore, compared with the existing prescription, the prescription of the present invention has a faster dissolution rate of estradiol and a high cumulative dissolution rate, thereby providing a guarantee for drug absorption and high bioavailability, while making the dissolution rate of dydrogesterone moderate to avoid irritation to the stomach.
[0052] The present invention is described in detail below through specific examples.
[0053] The weight parts of each component in Examples 1 to 4 and Comparative Examples 5 to 7 are shown in Table 1:
[0054] Table 1
[0055]
[0056] The particle size distributions of estradiol and dydrogesterone in Examples 1 to 4 and Comparative Examples 5 to 7 are shown in Table 2:
[0057] Table 2
[0058]
[0059] Embodiments 1 to 4
[0060] Made into 1000 tablets, each tablet is about 140 mg.
[0061] Preparation method:
[0062] (1) Weigh the prescribed amount of dydrogesterone, 1 / 2 the prescribed amount of lactose, corn starch, and colloidal silicon dioxide into a wet granulator and mix for 10 minutes.
[0063] (2) Start stirring and shearing, add 1 / 2 of the prescribed amount of HPMC solution prepared to a concentration of 12% within 2 to 3 minutes, and continue granulating for 3 minutes. Pass the wet granules through a 4*4 sieve, and then dry them in a fluidized bed until the moisture content is 1 to 3%. Then pass the dried granules through a 1.0 mm sieve to size the granules.
[0064] (3) Add 1 / 2 of the prescribed amount of magnesium stearate and mix for 5 minutes. Set aside.
[0065] (4) Weigh the prescribed amount of estradiol, sodium lauryl sulfate, 1 / 2 the prescribed amount of lactose, corn starch, and colloidal silicon dioxide, add them into a wet granulator and mix for 10 minutes.
[0066] (5) Start stirring and shearing, add 1 / 2 of the prescribed amount of HPMC solution prepared to a concentration of 12% within 2 to 3 minutes, and continue granulating for 3 minutes. Pass the wet granules through a 4*4 sieve, and then dry them in a fluidized bed until the moisture content is 1 to 3%. Then pass the dried granules through a 1.0 mm sieve to size the granules.
[0067] (6) Add 1 / 2 of the prescribed amount of magnesium stearate and mix for 5 minutes. Set aside.
[0068] (7) Using a double-layer tablet press, the granules obtained in step 3 and step 6 are tableted.
[0069] (8) Film coating premix is used for coating, and the concentration of the coating solution is 12%.
[0070] Comparative Example 5
[0071] The preparation process is the same as that of Examples 1 to 4, except that sodium dodecyl sulfate is not added in step (4).
[0072] Comparative Example 6
[0073] Made into 1000 tablets, each tablet is about 140 mg.
[0074] Preparation method:
[0075] (1) Weigh the prescribed amount of dydrogesterone, estradiol, lactose, corn starch, colloidal silicon dioxide, and sodium lauryl sulfate into a wet granulator and mix for 10 minutes.
[0076] (2) Start stirring and shearing, add the prescribed amount of hydroxypropyl methylcellulose solution prepared to a concentration of 12% within 2 to 3 minutes, and continue granulating for 3 minutes. Pass the wet granules through a 4*4 sieve, and then dry them in a fluidized bed until the moisture content is 1 to 3%. Then pass the dried granules through a 1.0 mm sieve to size the granules.
[0077] (3) Add the prescribed amount of magnesium stearate and mix for 5 minutes for later use.
[0078] (4) Using a tablet press to compress the granules in step 3.
[0079] (5) Film coating premix is used for coating, and the concentration of the coating solution is 12%.
[0080] Comparative Example 7
[0081] The preparation process is the same as that of Comparative Example 5, except that the particle size of estradiol is different.
[0082] Results test:
[0083] 1. Dissolution curve
[0084] The dissolution rates of the samples prepared in the above Examples 1 to 4 and Comparative Examples 5 to 7 were measured under different conditions.
[0085] The dissolution test method is as follows: Determine according to the dissolution test method (Method 2, Part 4 General Rules 0931 of the 2020 Edition of the Chinese Pharmacopoeia).
[0086] The different dissolution conditions are as follows:
[0087] Condition 1: Use 900 ml of 0.1% sodium dodecyl sulfate, pH 1.2 solution as the dissolution medium, rotate at 50 revolutions per minute, operate according to the method, and take samples after 10, 15, 30, 45, and 60 minutes respectively.
[0088] Condition 2: Use 900 ml of 0.1% sodium dodecyl sulfate, pH 4.5 solution as the dissolution medium, rotate at 50 revolutions per minute, operate according to the method, and take samples after 10, 15, 30, 45, and 60 minutes.
[0089] Condition 3: Use 900 ml of 0.1% sodium dodecyl sulfate, pH 6.8 solution as the dissolution medium, rotate at 50 revolutions per minute, operate according to the method, and take samples after 10, 15, 30, 45, and 60 minutes.
[0090] The different dissolution conditions detection methods are as follows:
[0091] Take 10ml of the solution, filter it, and take the filtrate as the test solution. Take about 10mg of estradiol reference substance and about 50mg of dydrogesterone reference substance, accurately weigh them, put them in the same 100ml volumetric flask, add 10ml of alcohol and ultrasonically dissolve them, let them cool, dilute them to the scale with the dissolution medium, and shake them well. Accurately measure 1ml, put it in a 25ml volumetric flask, dilute it to the scale with the dissolution medium, shake it well, and use it as the reference solution. Test according to high performance liquid chromatography (Appendix ⅤD of Part II of the Chinese Pharmacopoeia 2020 Edition). Use octadecylsilane bonded silica gel as the filler; acetonitrile-water (45:55) as the fluidity; the column temperature is 45°C; the detection wavelength is 205nm. The tailing factors of the estradiol peak and the dydrogesterone peak should not be greater than 2.0. Accurately measure 20 μl of the reference solution and the test solution, respectively, and inject them into the liquid chromatograph. Record the chromatogram and calculate the dissolution amount of estradiol and dydrogesterone in each tablet according to the external standard method based on the respective peak areas.
[0092] The results are shown in Tables 3 to 5 below:
[0093] Table 3 Dissolution of 0.1% sodium dodecyl sulfate in pH 1.2 medium (%)
[0094]
[0095] Table 4 Dissolution of 0.1% sodium dodecyl sulfate in pH 4.5 medium (%)
[0096]
[0097]
[0098] Table 5 Dissolution of 0.1% sodium dodecyl sulfate in pH 6.8 medium (%)
[0099]
[0100] It can be seen from the above dissolution test results that the dissolution rate of estradiol in the estradiol dydrogesterone tablets of the embodiment of the present invention is fast, and the dissolution amount in 15min in pH 1.2, pH 4.5, and pH 6.8 media exceeds 80%, and the cumulative dissolution is high, and the cumulative dissolution in 60min is above 95%. Compared with Comparative Examples 5 and 7, the dissolution rate and cumulative dissolution are significantly improved.
[0101] It can be seen from Comparative Example 6 that granulating sodium lauryl sulfate with estradiol, dydrogesterone and other excipients together will lead to too fast dissolution of dydrogesterone.
[0102] It can be seen from Comparative Examples 5 and 7 that when the particle size D90 of estradiol is reduced to 10 μm, further reducing the particle size has no significant effect on improving the dissolution rate.
[0103] 2. Stability test
[0104] The estradiol dydrogesterone tablets prepared according to the above-mentioned examples and comparative examples were placed under high temperature (40°C ± 2°C) and high humidity (relative humidity 75% ± 5%) for 6 months, and the estradiol-related substances in each sample were determined.
[0105] The related substance detection method is as follows:
[0106] Chromatographic conditions: octadecylsilane bonded silica gel was used as filler, acetonitrile-water (425:600) was used as fluidity, column temperature was 40°C, and the detection wavelength of estradiol was 220 nm.
[0107] Take 20 tablets of this product, place them in a 200ml brown volumetric bottle, add 20ml of water, ultrasonically disintegrate, add 80ml of acetonitrile, ultrasonically disintegrate for 15 minutes, cool, dilute to scale with water, shake well, filter, accurately measure 25ml of the filtrate, place it in a 50ml volumetric bottle, dilute to scale with fluidity, shake well as estradiol test solution; accurately weigh 10mg of estradiol reference substance, place it in a 100ml brown bottle, add 40ml of acetonitrile, ultrasonically dissolve, cool, dilute to scale with water, shake well as reference substance solution. Accurately measure 20μl of the test substance and reference substance solution respectively, inject them into the liquid chromatograph respectively, and record the chromatogram to twice the retention time of the main peak. If the chromatogram of the test solution shows impurity peaks, calculate the peak area according to the external standard method. Divide the calculation results of each degradation product by the relative response factor (RRF) in the following table. The relative retention time, relative response factor and limit of each degradation product are detailed in Table 6 (the peak with a relative retention time less than 0.4 is the excipient peak and is not counted).
[0108] Table 6
[0109] Relative retention time Relative Response Factor (RRF) limit(%) 6-Keto-estradiol 0.49 2.51 Not more than 0.5 Δ9,11-estradiol 0.88 1.95 Not more than 0.5 Estradiol 1.00 1.00 - 17α-estradiol 1.20 1.00 Not more than 0.3 Estrone 1.43 1.00 Not more than 0.5 Unknown degradation products - 1.00 Not more than 0.5 Total amount of degradation products - - No more than 1.5
[0110] The determination results of the relevant substance contents are shown in Table 7:
[0111] Table 7
[0112]
[0113] The above stability results show that the impurities in comparative example 6 increased significantly, from which it can be seen that the direct contact of estradiol, sodium lauryl sulfate, and dydrogesterone composition increased the instability of estradiol. Examples 1 to 4 of the present invention have good stability, and there is no significant increase in impurities during the stability placement process.
[0114] The above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Therefore, any simple modification, equivalent change and modification made to the above embodiment according to the technical essence of the present invention without departing from the content of the technical solution of the present invention shall fall within the scope of protection of the technical solution of the present invention.
Claims
1. An estradiol dydrogesterone tablet composition, characterized in that: It includes the following components in parts by weight: 1.0-2.5 parts of estradiol, 7.5-12.5 parts of dydrogesterone, 100-115 parts of filler, 10-18 parts of disintegrant, 1.5-3.5 parts of binder, 0.7-1.4 parts of solubilizer, 0.8-1.8 parts of glidant and 0.5-1 part of lubricant; The solubilizing agent is sodium lauryl sulfate.
2. The estradiol dydrogesterone tablet composition according to claim 1, characterized in that It is a double-layer tablet, wherein one layer comprises dydrogesterone, a filler, a disintegrant, a binder, a glidant and a lubricant, and the other layer comprises estradiol, a filler, a disintegrant, a binder, a solubilizer, a glidant and a lubricant.
3. The estradiol dydrogesterone tablet composition according to claim 2, characterized in that: The weight portions of filler, disintegrant, binder, glidant and lubricant in the two layers of the double-layer tablet are the same.
4. The estradiol dydrogesterone tablet composition according to claim 1, characterized in that The particle size of the estradiol is controlled to be less than 11 μm at D90.
5. The estradiol dydrogesterone tablet composition according to any one of claims 1 to 4, characterized in that: The composition further comprises 3 to 5 parts of coating agent.
6. The estradiol dydrogesterone tablet composition according to any one of claims 1 to 4, characterized in that: The filler includes one or more of lactose, mannitol, sorbitol, dextrin or maltodextrin.
7. The estradiol dydrogesterone tablet composition according to any one of claims 1 to 4, characterized in that: The disintegrant comprises one or more of corn starch, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose or low-substituted hydroxypropyl cellulose.
8. A method for preparing the estradiol dydrogesterone tablet composition according to any one of claims 1 to 7, characterized in that: The steps include: S1. Evenly mix dydrogesterone with part of the filler, part of the disintegrant and part of the glidant, add part of the binder to granulate, and mix with part of the lubricant after drying; S2. The estradiol and the solubilizer, the remaining filler, the remaining disintegrant and the remaining glidant are mixed uniformly, the remaining binder is added for granulation, and the mixture is dried and mixed with the remaining lubricant; S3. The granules obtained in S1 and S2 are compressed into double-layer tablets.
9. The preparation method according to claim 8, characterized in that: Also includes: S4. The double-layer tablets are made into double-layer tablets by film coating.
10. Use of the estradiol dydrogesterone tablet composition according to any one of claims 1 to 7 in the preparation of a medicament for treating perimenopausal syndrome.
Citation Information
Patent Citations
Oral solid dosage forms containing a low dose of estradiol
CN101094656A
Didrogesterone tablet and production process thereof
CN116036033A
Didrogesterone tablet composition and preparation method thereof
CN117180214A
Cited By
Estradiol didrogesterone preparation and preparation method thereof
CN121129787A
